Comparison of the Effects of Deferasirox (Nanojade®) and Deferoxamine (Desferal®) on Serum Ferritin Level Changes in Major Beta-Thalassemia Patients: A Randomized Clinical Trial
محل انتشار: مجله بین المللی کودکان، دوره: 11، شماره: 12
سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 56
فایل این مقاله در 11 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_INJPM-11-12_003
تاریخ نمایه سازی: 16 دی 1402
چکیده مقاله:
Background: Different drugs with different mechanisms have been used to remove iron overload in thalassemia patients. This study aimed to compare the effects of Nanojade and Deferoxamine in reducing serum ferritin levels. Methods: This randomized clinical trial was conducted on ۴۱ major thalassemia patients. The selected patients were allocated to two groups by the permuted block randomization method. The first group was treated with Deferasirox (Nanojade) and the second group was treated with Deferoxamine (Desferal). All patients received the drugs at ۱۴ mg/kg. Blood samples were collected at baseline, after ۳ and ۶ months after intervention. Chi-square test, Mann-Whitney U-test, and Friedman test were used for analytical statistics at the significance level of ۰.۰۵. Results: ۵۱.۹% of patients in the Nanojade group and ۴۰% in the Desferal group were females. Before the intervention, no difference was observed in terms of basic and demographic information. Before the intervention, as well as ۳ months, and ۶ months after the intervention, none of the blood parameters in the studied groups were significantly different (p> ۰.۰۵). The overall mean ferritin levels had a significant decrease, in both groups, ۶ months after the intervention (PDeferasirox = ۰.۰۰۱ vs PDeferoxamine = ۰.۰۴۳); However, in the comparison between the two groups, no significant difference was observed between the levels of ferritin and creatinine at any of the time points (p> ۰.۰۵). Conclusions: Deferasirox oral tablet (Nanojade®) is as effective as an injectable form (deferoxamine (Desferal®)) in reducing serum ferritin in patients with beta-thalassemia major without causing nephrotoxic effects. Therefore, it can be a suitable alternative to its injectable form.
کلیدواژه ها:
Beta-thalassemia ، ، ، ، ، Deferoxamine ، ، ، ، ، Deferasirox ، ، ، ، ، Nanojade ، ، ، ، ، serum ferritin
نویسندگان
saeedeh Khorashadi Zadeh
Resident of Pediatrics, Department of Pediatrics, Faculty of Medicine. Birjand University of Medical Sciences, Birjand, South Khorasan Province, Iran.
Bita Bijari
Assistante professor of Social Medicine, Birjand University of Medical Sciences(BUMS
Tayyebeh Chahkandi
Resident of Pediatrics, Department of Pediatrics, Faculty of Medicine. Birjand University of Medical Sciences (BUMS), Birjand, South Khorasan Province, Iran
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :